Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

Pain in children has been historically undertreated. This was in part the result of misguided assumptions, such as children’s inability to experience pain because of an immature nervous system and the innocuous effects of untreated pain in children. In addition, limited knowledge of pediatric drug metabolism prevented a clear understanding of how to dose analgesics in children. Over the past two decades, there has been significant progress in the understanding of neuroanatomy, physiology, and pharmacology of analgesics in children, which has led to considerable advancements in pain management. This chapter discusses developmental anatomy and neurochemistry, pain assessment, pharmacologic treatment of pain, and regional techniques in pediatric patients.

The late fetus and infant are neurologically sophisticated in their ability to transmit pain signals and respond to stress.1 Cutaneous sensory nerve terminals are present in the perioral region at 7 weeks’ gestation and spread to all body areas by 20 weeks’ gestation. Nerve growth factors regulate the extension of peripheral nociceptive fibers into the dorsal spinal cord, with the larger A fibers entering prior to the C fibers at 8 to 12 weeks. At birth, A and C fiber territories overlap in the developing substantia gelatinosa.2 Therefore, the neonatal response to a nonspecific sensory stimulus is low threshold, nonspecific, and poorly organized. Noxious and non-noxious stimuli produce similar physiologic and behavioral infant responses, complicating an accurate assessment of pain.

In the central nervous system (CNS), the full complement of cortical neurons, approximately 1000 million, are present at 20 weeks’ gestation. Pain transmission pathways complete myelination in the spine and brain stem between 22 and 30 weeks’ gestation. Myelination extends up to the thalamus by 30 weeks, and to the cortex by 37 weeks or term. Cortical descending inhibition develops post-term.

Excitatory and inhibitory neurotransmitters and neuromodulators are present in the fetus, with the balance favoring excitation. Calcitonin gene-related peptide (CGRP), substance P, and the glutamate-NMDA systems are present at 8 to 10 weeks’ gestation. Enkephalin and vasoactive intestinal peptide (VIP) appear at 10 to 14 weeks. Catecholamines are present in late gestation, and serotonin at 6 weeks’ postnatal. Of note, the receptors for excitatory neurotransmitters are numerous and widely distributed in the neonate, regressing toward an adult system in the postnatal months. As well, in the developing nervous system, inhibitory chemicals, such as gamma-amino butyric acid (GABA) and glycine, may act as excitatory transmitters. In an experimental murine model, the spinal cord concentration of NMDA receptors, and their ligand-affinity, is greater in neonates than in older animals. NK-1 receptor density is also maximal in late fetal and early postnatal life; however, substance P levels are lower than adult levels at birth.3

Regarding stress responses, the functional neuroendocrine pathways between hypothalamus and pituitary are present at 21 weeks’ gestation. Corticotrophin-releasing factor (CRF) may stimulate fetal ACTH and β-endorphin from that time, and cortisol and β-endorphin increases have been assayed following intrauterine sampling for exchange ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.